1.2 OMIM# of the disease 120435.
1.3 Name of the analysed genes or DNA/chromosome segments MLH1, MSH2, MSH6, and PMS2.
OMIM# of the gene(s)
MLH1 (NM_000248, U07418), MSH2 (NM_000251, U03911), MSH6 (NM_000179, U54777), PMS2 (NM_000535).
Mutational spectrum
Point mutations, large deletions and duplications, promoter methylation.
Analytical methods
Stepwise analyses:
(1) Clinical selection 1 : Lynch-related cancer (colon, rectum, endometrium, urinary tract, small bowel, biliary tract, ovary, stomach). Sporadic before 50 years of age, first-degree relative or prior Lynch-related cancer. (2) Study of MMR function in tumour cells 2 : microsatellite DNA analysis-genotyping of the consensus panel of five mononucleotidic repeats defined in 1998. Immunohistochemical study of the four mismatch repair proteins MLH1, MSH2, MSH6, and PMS2 (in case of MSI or in the absence of genotyping). BRAF codon 600 characterisation by pyrosequencing, sequencing, TaqMan, SNaPshot, and so on (in case of absence of the MLH1 protein). (3) Germline analysis 3 : MSH2 and/or MLH1 screening for point mutations by pre-screening (DHPLC) or direct sequencing, and for large genomic anomalies by MLPA including promoter regions and EPCAM gene. MSH6 or PMS2 screening for point mutations by pre-screening or direct sequencing, and for large genomic anomalies by MLPA (in case of negative results for MSH2/MLH1 screening, according to the tumour MMR status). MLH1 promoter methylation characterisation by MSP, bisulphite pyrosequencing (useful for diagnostic purpose, not for predictive testing).
Analytical validation
Confirmation of mutation in an independent biological sample of the index case or an affected relative. In case of deletion/duplication of one exon, confirm with a second technique/kit based on different primers.
1.8 Estimated frequency of the disease in Germany (incidence at birth ('birth prevalence') or population prevalence) Prevalence in colorectal cancer patients about 1-3%. Prevalence in population about 1:500-1:1000. 
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if only a quantification can be made case by case.
Not high and dependent on the indication criteria.
Computed by predictive models.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case. Depends on age and family history. Above 95%.
Positive clinical predictive value (lifetime risk to develop the disease if the test is positive)
About 80%.
Negative clinical predictive value (probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: About 95% (lifetime risk of colorectal cancer, the most frequent Lynch-related cancer, is 4% in the general population).
Index case in that family had not been tested: This is an unusual and not recommended approach. 
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